Cardiovascular Transition of Care Specialist position

[Anonymous]

before this group came on board Brilinta sales were flat. 18 months later, the product is kicking Effient's ass and growing well across the nation. Explain that...

Wow, kicking Effient's ass? Two piss ant products battling for single digit share of the market. Do you really want to brag about that?

 

[Anonymous]

before this group came on board Brilinta sales were flat. 18 months later, the product is kicking Effient's ass and growing well across the nation. Explain that...

It is called time on market

 

[Anonymous]

before this group came on board Brilinta sales were flat. 18 months later, the product is kicking Effient's ass and growing well across the nation. Explain that...

And NONE of that is attributable to the TCS team. Absolute FACT. (Show me stats otherwise). The ridiculous DDD: NBRx ratio has not improved across the nation, nor has there ever been shown an increase in 2nd script and thereafter Rx fill rate. These are the specific areas TCS's were hired to address, and they have failed completely.

 

[Anonymous]

Someone just need to kill off this inventiv contract already. Waste of time and money.

 

[Anonymous]

Someone just need to kill off this inventiv contract already. Waste of time and money.

Someone is taking credit for coming up with this idea and will skew the numbers and outright lie if necessary to prove their brilliance. Once it is a known loser then they will shift the blame to someone at a lower level or someone replaces them and the new person kills it to show they can make the tough call. This history repeats itself year after year at AZ.

 

[Anonymous]

before this group came on board Brilinta sales were flat. 18 months later, the product is kicking Effient's ass and growing well across the nation. Explain that...

Lol. Only place B outsells E is Europe. Check US sales you nitwit

 

[Anonymous]

before this group came on board Brilinta sales were flat. 18 months later, the product is kicking Effient's ass and growing well across the nation. Explain that...

Did you ever take note that Eli Lilly has significantly dropped their promotional efforts for Effient? If Lilly were still in the game (of which they are not) not only would our sales still be flat but we would probably be going through a major downsizing because our sales force can't sell.

 

[Anonymous]

Someone is taking credit for coming up with this idea and will skew the numbers and outright lie if necessary to prove their brilliance. Once it is a known loser then they will shift the blame to someone at a lower level or someone replaces them and the new person kills it to show they can make the tough call. This history repeats itself year after year at AZ.

Exactly right but the trouble is that "someone" is usually a committee decision. NO ONE here at AZ can think for themselves and NO ONE has the guts enough to stand alone. Brilinta is a crappy product and a total waste of money. Using a bunch of nurses hasn't done much either. The smart move is to sell the product off and be done with it.

 

[Anonymous]

Where are my scrubs? Nurse come with me I'm going in the cath lab and I'll show the doctor what to do. This is how it's done.

 

[Anonymous]

Where is my stethoscope?

 

[Anonymous]

Exactly right but the trouble is that "someone" is usually a committee decision. NO ONE here at AZ can think for themselves and NO ONE has the guts enough to stand alone. Brilinta is a crappy product and a total waste of money. Using a bunch of nurses hasn't done much either. The smart move is to sell the product off and be done with it.

How is a drug that saves more lives crappy ?

 

[Anonymous]

How is a drug that saves more lives crappy ?

Don't believe everything you read.

Signed

Me Too

 

[Anonymous]

Lol. Only place B outsells E is Europe. Check US sales you nitwit

2013 B sales were 283 million with strong growth in Europe, Canada, and Australia. Interestingly Mr. Soriot had admitted that the company had dropped the ball when it came to U.S. pricing, but was making progress.

 

[Anonymous]

Don't believe everything you read.

Signed

Me Too

It is called a randomized clinical trial, evidenced based medicine with a strong p value and by the way the DOJ confirmed no tampering with data. If you don't believe in statiscal evidence. Pharma is not the place for you. You're correct in your assumption that B may not save lives but that is a statistcal possibility with all clinical trials.

 

[Anonymous]

It is called a randomized clinical trial, evidenced based medicine with a strong p value and by the way the DOJ confirmed no tampering with data. If you don't believe in statiscal evidence. Pharma is not the place for you. You're correct in your assumption that B may not save lives but that is a statistcal possibility with all clinical trials.

Oh please! Any half ass lawyer could walk all over the "evidenced based medicine". Ask yourself this, if Brilinta is so good then why is the market share so weak?

Doctors are not buying into the nonsense we are pushing down their throats.

Now go put your scrubs on and pretend your important to patient lives.

 

[Anonymous]

agree with above post. brilinta has done very little and most likely will continue to very little over the next couple years. it's a dog and most analyst agree. sell it and move on.

 

[Anonymous]

The AHA and ACC did update guidelines to recommend Brilinta over Clopidogrel for the management of patients with non–ST-elevation acute coronary syndromes (NSTE-ACS). That is a pretty good recommendation. I don't sell Brilinta, but it has had a slow uptake. Certainly some had to do with questioning of its clinical trials and the recommendation of using generic Clopidogrel first. Not sure why it hasn't picked up the pace, but perhaps it will over time.

 

[Anonymous]

The AHA and ACC did update guidelines to recommend Brilinta over Clopidogrel for the management of patients with non–ST-elevation acute coronary syndromes (NSTE-ACS). That is a pretty good recommendation. I don't sell Brilinta, but it has had a slow uptake. Certainly some had to do with questioning of its clinical trials and the recommendation of using generic Clopidogrel first. Not sure why it hasn't picked up the pace, but perhaps it will over time.

The only "pace over time" Brilinta will pick up is 12 months before it's ready to go off patent with deep discounts. This drug is a dog chasing it's tail with very little value over generic. Sell it off to a midsize pharma company make a few bucks and collect on the royalties. It's that simple.

 

[Anonymous]

It's a revolving door of nurses who bring no values to the selling platform.

 

[Anonymous]

Several of the Nurses in our area have taken upon themselves to go rouge by talking off label and educating outside of their scope of practice. We need to cut this contract loose and avoid any potential law suits.